JPS5521760B2 - - Google Patents

Info

Publication number
JPS5521760B2
JPS5521760B2 JP5623373A JP5623373A JPS5521760B2 JP S5521760 B2 JPS5521760 B2 JP S5521760B2 JP 5623373 A JP5623373 A JP 5623373A JP 5623373 A JP5623373 A JP 5623373A JP S5521760 B2 JPS5521760 B2 JP S5521760B2
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP5623373A
Other languages
Japanese (ja)
Other versions
JPS4941378A (OSRAM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5521760(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of JPS4941378A publication Critical patent/JPS4941378A/ja
Publication of JPS5521760B2 publication Critical patent/JPS5521760B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP5623373A 1972-05-19 1973-05-19 Expired JPS5521760B2 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (OSRAM) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
JPS4941378A JPS4941378A (OSRAM) 1974-04-18
JPS5521760B2 true JPS5521760B2 (OSRAM) 1980-06-12

Family

ID=20269234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5623373A Expired JPS5521760B2 (OSRAM) 1972-05-19 1973-05-19

Country Status (26)

Country Link
US (2) US3929768A (OSRAM)
JP (1) JPS5521760B2 (OSRAM)
AT (1) AT328630B (OSRAM)
BE (1) BE799727A (OSRAM)
CA (1) CA1002938A (OSRAM)
CH (1) CH595400A5 (OSRAM)
CS (1) CS178129B2 (OSRAM)
CY (1) CY1013A (OSRAM)
DD (1) DD104295A5 (OSRAM)
DE (1) DE2323215C3 (OSRAM)
DK (1) DK134783B (OSRAM)
ES (1) ES414673A1 (OSRAM)
FI (1) FI50631C (OSRAM)
FR (1) FR2185405B1 (OSRAM)
GB (1) GB1429922A (OSRAM)
HK (1) HK49179A (OSRAM)
HU (1) HU166680B (OSRAM)
IL (1) IL42155A (OSRAM)
KE (1) KE2970A (OSRAM)
NL (2) NL177493C (OSRAM)
NO (2) NO139640C (OSRAM)
PL (1) PL87765B1 (OSRAM)
SE (1) SE378109B (OSRAM)
SU (1) SU470954A3 (OSRAM)
YU (1) YU35896B (OSRAM)
ZA (1) ZA732955B (OSRAM)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24B1 (ro) * 1991-07-09 1994-05-31 Parfumerii Si Cosmetice Vioric Compozitie de substante odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
ES2107806T3 (es) * 1992-12-24 1997-12-01 Rhone Poulenc Rorer Ltd Nuevos esteroides.
HU221584B (hu) * 1993-01-08 2002-11-28 Aktiebolaget Astra Új vastagbél- (colon) vagy csípőbél- (ileum) specifikus, cukortartalmú szteroidszármazékok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
ATE172739T1 (de) 1993-04-02 1998-11-15 Byk Gulden Lomberg Chem Fab Neue prednisolonderivate
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE60021720T2 (de) 1999-05-04 2006-06-01 Strakan International Ltd. Androgen glykoside und die androgenische aktivität davon
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
CA2561315A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
US20070135398A1 (en) * 2005-11-02 2007-06-14 Pierluigi Rossetto Process for the preparation of ciclesonide
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DK2074093T3 (da) 2006-08-22 2012-11-19 Ranbaxy Lab Ltd Fremgangsmåde til fremstilling af matrix metalloproteinase-inhibitorer og chirale hjælpemidlerdel dertil
EP2086948A2 (en) * 2006-09-22 2009-08-12 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
KR20120090100A (ko) 2006-12-26 2012-08-16 파마시클릭스, 인코포레이티드 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
CA2680625C (en) * 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
WO2009045539A2 (en) * 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
ES2401057T3 (es) * 2008-03-13 2013-04-16 Farmabios S.P.A. Procedimiento para la preparación de derivados de pregnano
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AR076807A1 (es) 2009-05-29 2011-07-06 Pearl Therapeutics Inc Composiciones metodos y sistemas para el suministro de dos o mas agentes activos mediante las vias respiratorias. metodo de preparacion composicion
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
PL2482822T3 (pl) 2009-10-01 2018-10-31 Adare Pharmaceuticals, Inc. Podawane doustnie kompozycje kortykosteroidowe
AU2010307198C9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013039488A1 (en) 2011-09-13 2013-03-21 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
CA2882306A1 (en) 2012-08-24 2014-02-27 Board Of Regents, The University Of Texas System Heterocyclic modulators of hif activity for treatment of disease
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
RU2015154720A (ru) 2013-05-22 2017-06-27 Перл Терапьютикс, Инк. Композиции, способы и системы для респираторной доставки трех или более активных средств
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3250211B1 (en) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
AU2018365946B2 (en) 2017-11-07 2025-08-28 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3737420A2 (en) 2018-01-08 2020-11-18 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
KR20220123229A (ko) 2019-12-17 2022-09-06 머크 샤프 앤드 돔 엘엘씨 Prmt5 억제제
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20240042437A (ko) 2021-07-09 2024-04-02 아스트라제네카 파마수티컬스 엘피 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템
JP2024545816A (ja) 2021-12-20 2024-12-12 アストラゼネカ・アクチエボラーグ エアロゾル薬物送達のための組成物、方法及びシステム
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
GEAP202516765A (en) 2022-10-25 2025-08-25 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
TW202430140A (zh) 2022-12-14 2024-08-01 美商默沙東有限責任公司 奧里斯他汀(auristatin)連接子藥物(payload)、醫藥組合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (OSRAM) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
SE378109B (OSRAM) 1975-08-18
ATA436573A (de) 1975-06-15
FR2185405B1 (OSRAM) 1976-12-31
DD104295A5 (OSRAM) 1974-03-05
DK134783B (da) 1977-01-17
YU129173A (en) 1981-02-28
NO1994013I1 (no) 1994-08-31
SU470954A3 (ru) 1975-05-15
NL930025I1 (nl) 1993-06-01
IL42155A (en) 1977-06-30
NL177493C (nl) 1985-10-01
FR2185405A1 (OSRAM) 1974-01-04
DE2323215A1 (de) 1973-11-29
BE799727A (fr) 1973-09-17
CY1013A (en) 1979-11-23
FI50631B (OSRAM) 1976-02-02
IL42155A0 (en) 1973-07-30
DK134783C (OSRAM) 1977-06-06
ZA732955B (en) 1974-04-24
DE2323215C3 (de) 1978-03-30
ES414673A1 (es) 1976-07-01
CH595400A5 (OSRAM) 1978-02-15
NO139640C (no) 1979-04-18
FI50631C (fi) 1976-05-10
NO139640B (no) 1979-01-08
PL87765B1 (OSRAM) 1976-07-31
YU35896B (en) 1981-08-31
US3929768A (en) 1975-12-30
JPS4941378A (OSRAM) 1974-04-18
NL177493B (nl) 1985-05-01
US3983233A (en) 1976-09-28
AU5525373A (en) 1974-11-07
CS178129B2 (OSRAM) 1977-08-31
AT328630B (de) 1976-03-25
DE2323215B2 (de) 1977-08-11
HK49179A (en) 1979-07-27
NL7306978A (OSRAM) 1973-11-21
HU166680B (OSRAM) 1975-05-28
KE2970A (en) 1979-07-20
CA1002938A (en) 1977-01-04
GB1429922A (en) 1976-03-31

Similar Documents

Publication Publication Date Title
DK134783C (OSRAM)
JPS4921097A (OSRAM)
FR2207742B1 (OSRAM)
JPS5325887B2 (OSRAM)
JPS4965722U (OSRAM)
JPS48100537U (OSRAM)
JPS48112760U (OSRAM)
JPS4994451U (OSRAM)
JPS5229236Y2 (OSRAM)
JPS48103612U (OSRAM)
DE2233988A1 (OSRAM)
JPS4987778A (OSRAM)
JPS4961998A (OSRAM)
JPS4940680U (OSRAM)
CH572639A5 (OSRAM)
CH565977A5 (OSRAM)
CH568695A5 (OSRAM)
CH562478A5 (OSRAM)
CH561884A5 (OSRAM)
CH568592A5 (OSRAM)
CH570364A5 (OSRAM)
CH566159A5 (OSRAM)
CH562496A5 (OSRAM)
CH571050A5 (OSRAM)
CH560986A5 (OSRAM)